mRNA-1010

Phase 2RNA therapy

Moderna

mRNA-1010 is one of 65 biologic programs targeting Severe Acute Respiratory Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe Acute Respiratory SyndromeActive, not recruiting

InfluenzaActive, not recruiting

Severe Acute Respiratory SyndromePhase 1

Active, not recruiting

InfluenzaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

Fluzone

GSK

Preclinical

37 3

mRNA-1010

Moderna

Phase 2

8 4

Crestor

AstraZeneca

Preclinical

1 5

Trexall

Alnylam Pharmaceuticals

Preclinical

1 6

Avigan

AAppili Therapeutics Inc.

Preclinical

6 7

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 8

COMIRNATY

Pfizer

Preclinical

1 9

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 10

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Influenza8 trials

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Completed· Moderna logo

Moderna·Phase 3·NCT05566639·22,502 enrolled

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

Completed· Moderna logo

Moderna·Phase 1/2·NCT05375838·550 enrolled

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

Completed· Moderna logo

Moderna·Phase 1/2·NCT04956575·885 enrolled

Show 5 more trials

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

Completed· Moderna logo

Moderna·Phase 1/2·NCT05827068·698 enrolled

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Completed· Moderna logo

Moderna·Phase 3·NCT05415462·6,102 enrolled

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

Completed· Moderna logo

Moderna·Phase 3·NCT06602024·40,817 enrolled

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Completed· Moderna logo

Moderna·Phase 3·NCT05827978·8,411 enrolled

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults

Completed· Moderna logo

Moderna·Phase 1/2·NCT05333289·572 enrolled

Immunogenicity2 trials

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

Completed· Moderna logo

Moderna·Phase 2·NCT05606965·172 enrolled

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

Completed· Moderna logo

Moderna·Phase 2·NCT05868382·270 enrolled

mRNA Vaccine1 trial

A Study of Modified mRNA Vaccines in Healthy Adults

Completed· Moderna logo

Moderna·Phase 1·NCT05397223·308 enrolled

Severe Acute Respiratory Syndrome1 trial

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

Completed· Moderna logo

Moderna·Phase 1·NCT05585632·392 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for mRNA-1010. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mRNA-1010 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mRNA-1010. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 2[1]
Company: Moderna

mRNA-1010

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Influenza8 trials

Immunogenicity2 trials

mRNA Vaccine1 trial

Severe Acute Respiratory Syndrome1 trial

References

Drug Info

Quick Facts

Related News